Humulin M3 Kwikpen

Humulin M3 Kwikpen is a pre‑filled KwikPen injector that contains insulin human (rDNA) as its active ingredient. It is supplied for subcutaneous administration and is marketed in the European Union as a prescription‑only antidiabetic medication. The device delivers rapid‑acting insulin to help regulate blood glucose in people, for patients, with diabetes and is designed for ease of use, providing accurate dosing with each pen click daily.

Humulin M3 Kwikpen is indicated for the management of hyperglycemia in adults with diabetes.

- Treatment of type 1 diabetes mellitus when rapid‑acting insulin is needed. - Treatment of type 2 diabetes mellitus as part of a comprehensive glycemic control plan. - Use as a mealtime (prandial) insulin to cover carbohydrate intake. - Combination with a long‑acting basal insulin for basal‑bolus therapy. - Suitable for patients who require multiple daily injections (MDI) for optimal control. - Can be employed during transition from insulin pump therapy to injection therapy.

Adverse reactions to Humulin M3 Kwikpen are generally related to its insulin activity and injection site.

Common: - Hypoglycemia, presenting as sweating, shakiness, or confusion. - Mild pain, redness, or swelling at the injection site. - Lipodystrophy, including localized lipoatrophy or lipohypertrophy. - Modest weight gain associated with improved glycemic control. - Transient blurred vision or dizziness. - Nausea or mild gastrointestinal discomfort. - Localized bruising or hematoma at injection site.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions ranging from urticaria to anaphylaxis. - Insulin‑induced edema or heart failure exacerbation in susceptible patients. - Serum sickness‑like reaction with fever, rash, and arthralgia.

When using Humulin M3 Kwikpen, several precautions should be considered to ensure safe and effective therapy.

- Store in a refrigerator between 2 °C and 8 °C; do not freeze and discard after 28 days of in‑use. - Rotate injection sites within the abdomen, thigh, or upper arm to reduce lipodystrophy. - Perform frequent blood‑glucose monitoring, especially when initiating therapy or changing dose. - Adjust insulin dose during periods of illness, increased physical activity, or emotional stress. - Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced. - Pregnancy and lactation categories are not established; discuss risks and benefits with a healthcare professional.

Humulin M3 Kwikpen may interact with other medicines that affect blood glucose, insulin metabolism, or hypoglycemia awareness.

Avoid: - Simultaneous administration of other rapid‑acting insulin preparations without appropriate dose reduction. - Beta‑adrenergic blockers that can mask signs of hypoglycemia. - Monoamine oxidase inhibitors, which may enhance insulin’s glucose‑lowering effect. - Thyroid hormones that may alter insulin sensitivity.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk. - Corticosteroids or thiazide diuretics that raise blood glucose and may require higher insulin doses. - Alcohol consumption, which can cause delayed hypoglycemia. - Growth hormone therapy, which can increase insulin resistance.